At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 755 enrolled
Drug / intervention
LY2189265 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating LY2189265 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 755 participants across 76 sites in 8 countries.
Detailed Summary
The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Brazil, Canada, Czechia, Denmark, India, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionSep 2011
Study CompletionJan 2012
TodayJul 2026
First PostedJun 23, 2010
Enrollment StartJun 1, 2010
Primary CompletionSep 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.0 years ago
Interventions
LY2189265drug
Administered as a subcutaneous injection once weekly for 26 weeks
Placebodrug
Administered as a subcutaneous injection once weekly for 26 weeks